Yahoo Finance

RedHill Biopharma Announces U.S. Commercialization Agreement for FDA-Approved GI Product Esomeprazole Strontium Delayed-Release Capsules

RedHill was granted the exclusive rights to promote Esomeprazole Strontium Delayed-Release (DR) Capsules to gastroenterologists in certain U.S. territories Esomeprazole Strontium DR Capsules 49.3 mg ...
Yahoo Finance

RedHill Biopharma Initiates Promotion of Esomeprazole Strontium Delayed-Release Capsules 49.3 mg in the U.S.

TEL-AVIV, Israel and RALEIGH, N.C., Sept. 13, 2017 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (RDHL) (Tel-Aviv Stock Exchange:RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company ...
Business Wire

Amneal Launches Esomeprazole Strontium 49.3 mg Delayed-Release Capsules, a Pharmaceutical Alternative to Nexium

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals LLC today announced the launch of its branded Esomeprazole Strontium 49.3 mg delayed-release capsules. Esomeprazole Strontium contains the ...
Business Wire

Federal Appeals Court Ruling Affirms Amneal’s Green Light to Market New Esomeprazole Strontium Delayed-Release Capsules

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals LLC today applauded the December 19 decision by the U.S. Court of Appeals for the Federal Circuit (CAFC) in favor of South Korea-based Hanmi ...
Mena FN

RedHill Biopharma Announces U.S. Commercialization Agreement for FDA-Approved GI Product Esomeprazole Strontium Delayed-Release Capsules

Esomeprazole Strontium DR Capsules 49.3 mg is a prescription proton pump inhibitor (PPI) indicated for adults for the treatment of gastroesophageal reflux disease (GERD), risk reduction of ...